Point72 Asset Management, L.P. 13D and 13G filings for Avalo Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-26 5:10 pm Purchase | 2026-05-22 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Point72 Asset Management, L.P. | 2,710,817 5.200% | 2,083,315 (+332.00%) | Filing |
| 2026-02-17 4:33 pm Sale | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Point72 Asset Management, L.P. | 627,502 3.500% | -426,481 (-40.46%) | Filing |
| 2025-11-14 4:11 pm Purchase | 2025-09-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Point72 Asset Management, L.P. | 1,053,983 8.000% | 465,351 (+79.06%) | Filing |
| 2025-08-05 4:58 pm Purchase | 2025-08-04 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Point72 Asset Management, L.P. | 588,632 5.400% | 586,132 (+23445.28%) | Filing |
| 2024-02-14 10:02 am Purchase | 2023-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Point72 Asset Management, L.P. | 2,500 0.300% | 414 (+19.85%) | Filing |